NYXTHRACIS

This brand name is authorized in Austria, Estonia, Italy, Lithuania, Poland

Active ingredients

The drug NYXTHRACIS contains one active pharmaceutical ingredient (API):

1 Obiltoxaximab
UNII 29Z5DNL48C - OBILTOXAXIMAB

Obiltoxaximab is a monoclonal antibody that binds the protective antigen (PA) of B. anthracis. Obiltoxaximab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and oedema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin.

Read about Obiltoxaximab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
NYXTHRACIS Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J06BC04 J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BC Antibacterial monoclonal antibodies
Discover more medicines within J06BC04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1833678
Country: IT Agenzia del Farmaco Identifier(s): 049226018
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1091351

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.